Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis

被引:0
作者
S. V. Ramagopalan
G. C. DeLuca
K. M. Morrison
B. M. Herrera
D. A. Dyment
M. R. Lincoln
S.-M. Orton
M. J. Chao
A. Degenhardt
M. Pugliatti
A. D. Sadovnick
S. Sotgiu
G. C. Ebers
机构
[1] Level 3,Dept. of Clinical Neurology, University of Oxford
[2] West Wing,Wellcome Trust Centre for Human Genetics
[3] John Radcliffe Hospital,Dept. of Medical Genetics and Faculty of Medicine
[4] University of Oxford,Institute of Clinical Neurology
[5] Division of Neurology,undefined
[6] University of British Columbia,undefined
[7] University of Sassari,undefined
来源
Journal of Neurology | 2008年 / 255卷
关键词
multiple sclerosis; genetics; outcome;
D O I
暂无
中图分类号
学科分类号
摘要
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system unsurpassed for its variability in disease outcome. As little is conclusively known about MS disease mechanisms, we have selected a variety of candidate genes that may influence the prognosis of the disease based on their function. A cohort of sporadic MS cases, taken from opposite extremes of the putative distribution of long-term outcome using the most stringent clinical criteria to date, was used to determine the role of on MS disease severity. The MS cases selected represent the prognostic best 5 % (benign MS) and worst 5 % (malignant MS) of cases in terms of clinical outcome assessed by the EDSS. Genotyping the two sets of MS patients (112 benign and 51 malignant) and a replication cohort from Sardinia provided no evidence to suggest that the genes selected have any outcome modifying activity, although small effects of these genes cannot be ruled out.
引用
收藏
相关论文
共 50 条
  • [21] Disease-Modifying Therapy of Pediatric Multiple Sclerosis
    Tanuja Chitnis
    [J]. Neurotherapeutics, 2013, 10 : 89 - 96
  • [22] Emerging multiple sclerosis disease-modifying therapies
    Giacomini, Paul S.
    Darlington, Peter J.
    Bar-Or, Amit
    [J]. CURRENT OPINION IN NEUROLOGY, 2009, 22 (03) : 226 - 232
  • [23] Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
    Longbrake, Erin E.
    Parks, Becky J.
    Cross, Anne H.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2013, 13 (11)
  • [24] Emerging Disease-Modifying Therapies in Multiple Sclerosis
    Perumal, Jai
    Khan, Omar
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2012, 14 (03) : 256 - 263
  • [25] Disease-Modifying Therapy of Pediatric Multiple Sclerosis
    Chitnis, Tanuja
    [J]. NEUROTHERAPEUTICS, 2013, 10 (01) : 89 - 96
  • [26] Current disease-modifying therapies in multiple sclerosis
    Kieseier, BC
    Hartung, HP
    [J]. SEMINARS IN NEUROLOGY, 2003, 23 (02) : 133 - 145
  • [27] Is physical exercise a multiple sclerosis disease modifying treatment?
    Motl, Robert W.
    Pilutti, Lara A.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (08) : 951 - 960
  • [28] Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
    Jalkh, Georges
    Abi Nahed, Rachelle
    Macaron, Gabrielle
    Rensel, Mary
    [J]. VACCINES, 2021, 9 (01) : 1 - 30
  • [29] Current Disease-Modifying Treatment of Multiple Sclerosis
    Derwenskus, Joy
    [J]. MOUNT SINAI JOURNAL OF MEDICINE, 2011, 78 (02): : 161 - 175
  • [30] Disease-modifying treatments for progressive multiple sclerosis
    Comi, Giancarlo
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 1428 - 1436